GRM2 and Alzheimer disease: The mechanisms of how both activation by psychedelic and non-psychedelic agonists and blockade by traditional antidepressants or more selective antagonists of the target receptors including NMDA, mGluR2/3, M1, M2, and 5-HT2 receptors, can produce AD-like activity in animal models of depression is still an open question.